Golimumab for the treatment of ulcerative colitis

The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Löwenberg, Mark, de Boer, Nanne KH, Hoentjen, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958527/
https://www.ncbi.nlm.nih.gov/pubmed/24648749
http://dx.doi.org/10.2147/CEG.S48741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958527/
https://www.ncbi.nlm.nih.gov/pubmed/24648749
http://dx.doi.org/10.2147/CEG.S48741

Ejemplares similares